Regarding SGLT2-i, the CREDENCE trial was specifically designed to assess directly renal outcomes with a composite criterion of end-stage renal disease, doubling of creatinine level, and death from renal causes, which was decreased by 34% with canagliflozin use in patients with T2D [26]. Here, SLC5A2 is linked to stage 5 chronic kidney disease.